Evidence map›Paper›PMID 36198435›Full record

ArticleInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society2022

Factors contributing to delays in initiation of front-line cervical cancer therapy: disparities in a diverse south Florida population.

Molly Roy, Lindsey Finch, Deukwoo Kwon, Scott E Jordan, Sina Yadegarynia, Aaron Howard Wolfson, Brian Slomovitz, Lorraine Portelance, Marilyn Huang

Abstract read
In one paragraph

Article in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Molly RoyGynecologic Oncology, University of Miami Miller School of Medicine/Jackon Memorial Hospital, Miami, Florida, USA.ORCID http://orcid.org/0000-0002-3715-6776
Lindsey FinchObstetrics and Gynecology, Jackson Memorial Hospital, Miami, Florida, USA.
Deukwoo KwonDepartment of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida, USA.
Scott E JordanGynecologic Oncology, University of Miami Miller School of Medicine/Jackon Memorial Hospital, Miami, Florida, USA.
Sina YadegaryniaUniversity of Miami Miller School of Medicine, Miami, Florida, USA.
Aaron Howard WolfsonRadiation Oncology, University of Miami Health System, Miami, Florida, USA.
Brian SlomovitzGynecologic Oncology, Mount Sinai Medical Center, Miami Beach, Florida, USA.
Lorraine PortelanceRadiation Oncology, University of Miami Health System, Miami, Florida, USA.
Marilyn HuangGynecologic Oncology, Mount Sinai Medical Center, Miami Beach, Florida, USA m.huang@med.miami.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveDelay in initiating cervical cancer treatment may impact outcomes. In a cohort of patients initially treated by surgery, chemoradiation, chemotherapy, or in a clinical trial, we aim to define factors contributing to prolonged time to treatment initiation.

methodsData from patients initiating treatment for cervical cancer at a single institution was abstracted. Time to treatment initiation was defined as the interval from the date of cancer diagnosis to the date of treatment initiation. Poisson regression model was used for analysis.

resultsOf 274 patients studied, the median time to treatment initiation was 60 days (range 0-551). The median times to initiate surgery (54 days, range 3-96) and chemoradiation (58 days, range 4-187) were not significantly different (relative risk (RR) 1.01, 95% CI 0.98 to 1.04, p=0.54). The shortest median initiation time was for chemotherapy (47 days; RR 1.13, 95% CI 1.08 to 1.19, p<0.0001) and the longest was for clinical trial (62 days; RR 1.18, 95% CI 1.12 to 1.24, p<0.0001). Charity care (RR 1.09, 95% CI 1.05 to 1.14, p<0.0001), Medicare or Medicaid (RR 1.10, 95% CI 1.06 to 1.14, p<0.0001), and self-pay (RR 1.38, 95% CI 1.32 to 1.45, p<0.0001) delayed treatment initiation more than private insurance. Hispanic White women (RR 0.69, 95% CI 0.66 to 0.73, p<0.0001) had a shorter treatment initiation time compared with non-Hispanic White patients, while Afro-Caribbean/Afro-Latina women (RR 0.86, 95% CI 0.81 to 0.90, p<0.0001) and African-American patients (RR 1.13, 95% CI 1.07 to 1.19, p<0.0001) had longer initiation times. Spanish speaking patients did not have a prolonged treatment initiation (RR 0.68, 95% CI 0.66 to 0.71, p<0.0001), though Haitian-Creole speaking patients did (RR 1.07, 95% CI 1.01 to 1.13, p<0.002). Diagnosis at an outside institution delayed treatment initiation time (RR 1.24, 95% CI 1.18 to 1.30, p<0.0001) compared with diagnosis at the cancer center.

conclusionFactors associated with prolonged time to treatment initiation include treatment modality, insurance status, language spoken, and institution of diagnosis. By closely examining each of these factors, barriers to treatment can be identified and modified to shorten treatment initiation time.

Indexed as

Uterine Cervical NeoplasmsAgedFemaleFloridaHaitiHealthcare DisparitiesHispanic or LatinoHumansMedicareUnited StatesCervical CancerRadiationSurgery

Identifiers

PMID36198435
PMCPMC9664089

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.